https://charts.traderzeitung.de/phases/US44975P1030 string(1418) "{"isin":"US44975P1030","name":"NovaBridge Biosciences","stock_id_xnas":11001747,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.61,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.615,"close_at":"2026-09-22 15:18:00","complete":true,"perf_pct":0.3106},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.59,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-1.548},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.52,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-4.4025},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

I-MAB Aktie News & Nachrichten

[WKN: A2PVC6 | Symbol: NBP]

Realtimekurs

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über I-MAB gefunden werden.

I-MAB Nachrichtenticker öffnen

MT Newswires 29.06.2026 20:46 Uhr

NovaBridge Biosciences ernennt Srishti Gupta zum CEO

02:45 PM EDT, 06/29/2026 (MT Newswires) -- NovaBridge Biosciences (NBP) teilte am Montag mit, dass es Srishti Gupta mit Wirkung zum Mittwoch zum Chief

MT Newswires 16.06.2026 13:42 Uhr

NovaBridge Biosciences erhält US-FDA-Fast-Track-Status für gastroösophageale Krebstherapie

07:41 AM EDT, 06/16/2026 (MT Newswires) -- NovaBridge Biosciences (NBP) teilte am Dienstag mit, dass die US-amerikanische Food and Drug Administration